| Product Unit Size | Cost | Quantity | Stock |
|---|
Ulixertinib is an ERK1/2 inhibitor that has been found to impair proliferation, arrest cell cycle, and induce apoptosis in lymphoma cell lines. Ulixertinib has also demonstrated effectiveness in several models that show either intrinsic or acquired resistance to MAPK pathway inhibitors.
| Cas No. | 869886-67-9 |
|---|---|
| Purity | ≥98% |
| Formula | C21H22Cl2N4O2 |
| Formula Wt. | 433.33 |
| IUPAC Name | N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide |
| Synonym | BVD-523, VRT752271 |
| Solubility | DMSO:86 mg/mL (198.46 mM) Ethanol:15 mg/mL (34.61 mM) Water:Insoluble |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Ding WJ, Tao WP, Zeng T, et al. Selective ERK inhibitor ulixertinib inhibits proliferation and induces apoptosis in lymphoma cell lines. Int J Clin Exp Med. 2017;9(6):10955-10962.
Germann U, Furey B, Roix J, et al. The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.